Pharmacoanalytic Core Laboratory

药物分析实验室(PAL)的使命是提供智力和分析支持 面向基础、转化型和临床科学家。对于基础科学研究人员，PAL在 将发现从“试管”发展到潜在的临床模式。潜在的抗癌或 使用体外和体内模型进一步开发源自实验室概念的诊断试剂 在PAL的智力支持下发展起来的。对于临床医生，PAL提供了分析和 药代动力学/药效学支持，以进一步了解可能 影响临床结果。 为了满足这些需要，PAL已经具备了制定具体分析方法的能力。 以及基于生物学的技术，以支持基本的、翻译的和临床的努力。这包括 酶联免疫吸附和高效液相色谱高灵敏定量方法的建立 串联质谱仪(LC-MS/MS)技术。基于LC-MS/MS的技术可以将 所需的样本量，从而允许在儿科人群中甚至在 小动物。此外，PAL还开发了使用LC-MS/MS来确定细胞内的方法 浓缩核苷及其合成代谢产物，包括活性成分三磷酸 核苷酸。这些技术也可以用来分析细胞内的核苷酸池，以研究细胞 导致核苷耐药的机制。此外，PAL还参与了临床设计 具有药代动力学成分的方案，并评估人体药代动力学结果 学习。 尽管有这些发展，PAL仍保持并加强了其核心分析能力 使用基于高效液相的检测方法，利用紫外和荧光检测。这些化验是可靠的分析方法。 能够支持强制进行药物水平测定的临床方案的能力。PAL培养了一名 环境，以加强基础、翻译和临床科学家之间的合作。

The mission of Pharmacoanalytical Laboratory (PAL) is to provide intellectual and analytical support to basic, translational and clinical scientists. For basic science investigators, the PAL assists in the development of discoveries from the "test tube" to potential clinical modalities. Potential anticancer or diagnostic agents derived from laboratory concepts are further developed using in vitro and in vivo models developed with intellectual support from the PAL. For clinicians, the PAL provides analytical and pharmacokinetic/pharmacodynamics support to further understand the underlying mechanisms that may influence clinical outcome. In an effort to meet these needs, the PAL has acquired the capacity to develop specific analytical and biologically-based techniques to support basic, translational and clinically-based efforts. This includes the development of highly sensitive quantification methods by using ELISA- and liquid chromatography tandem mass spectrometry (LC-MS/MS)-based technology. LC-MS/MS-based technology can minimize the amount of sample volume required, thus allowing serial drug analysis in pediatric populations and even in small animals. In addition, the PAL has developed methods using LC-MS/MS to determine intracellular concentration nucleosides and their anabolites that include the activated component, the triphosphate nucleotides. These techniques can also be used to analyze intracellular nucleotide pools to study cellular mechanisms that lead to nucleoside resistance. In addition, the PAL collaborates in the design of clinical protocols having a pharmacokinetic component and evaluates the results of human pharmacokinetic studies. Despite these developments, the PAL has maintained and enhanced its core analytical capacity using HPLC-based assays utilizing UV and fluorescence detection. These assays are reliable analytical capabilities that can support clinical protocols that mandate drug level determinations. The PAL fosters an environment to enhance collaboration between basic, translational and clinical scientists.